Abstract
The aim of the present study was to investigate the effect of liposome-encapsulation and liposome-size on the in vivo pharmacokinetics of interferon α-2b (IFNα-2b) following i.m. administration to rats, and whether there was any liver-targeting of these liposomes. Since liposomes of different sizes can be obtained by homogenization, the effect of homogenization on the IFNα-2b activity was also investigated. The pharmacokinetics of IFNα-2b solution (12.8 μg/kg) and IFNα-2b prepared in liposomes, including three mean sizes of 172 nm (12.2μg/kg), 113 nm (44.2, 11.0, and 2.8μg/kg, respectively), and 82 nm (13.1 μg/kg), were studied after a single i.m. dose to rats. Compared to a solution of IFNα-2b. administration of liposomal IFNα-2b resulted in a significantly prolonged tmax, the apparent elimination half life (t1/2β) was 2.3 times longer, both AUC0-∞ and MRT0-∞ were also clearly enhanced and greater accumulation was obtained in the liver (p < 0.05). The AUC0-∞ increased proportionally to the administered dose of IFNα-2b liposomes. Moreover, the size of liposomes ranging from 82 nm to 172 nm had no significant difference on the pharmacokinetic behavior in vivo (p > 0.05). In sum, compared with the free form, IFNα-2b encapsulated in liposomes can alter strikingly the pharmacokinetics properties following i.m. injection and if a liposomal size ranging from 82 nm to 172 nm was used, consistent pharmacokinetic behaviors of IFNα-2b was exhibited. The liposomal formulation apparently targeted the liver, offering a potential advantage for hepatitis B treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Awasthi, V. D., Garcia, D., Goins, B. A., and Phillips, W. T., Circulation and biodistribution profiles of long-circulating PEG-liposomes of various sizes in rabbits. Int. J. Pharm., 253, 121–132 (2003).
Behari, J. R., Gupta, S., Srivastava, S., and Srivastava, R. C., Influence of size of liposomes in potentiating the efficacy of encapsulated triethylenetetramine-hexaacetic acid (TTHA) against cadmium intoxication. Ind. Health, 31, 29–33 (1993).
Chonn, A. and Cullis, P. R., Recent advances in liposomal drug-delivery systems. Curr. Opin. Biotechnol., 6, 698–708 (1995).
Foser, S., Schacher, A., Weyer, K. A., Brugger, D., Dietel, E., Marti, S., and Schreitmüller, T., Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon α-2a (PEGASYS). Protein Expr. Purif., 30, 78–87 (2003).
Glue, P., Fang, J. W., Rouzier-Panis, R., Raffanel, C., Sabo, R., Gupta, S. K., Salfi, M., and Jacobs, S., Pegylated interferon α-2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin. Pharmacol. Ther., 68, 556–567 (2000).
Goldbach, P., Dumont, S., Kessler, R., Poindron, P., and Stamm, A., Preparation and characterization of interferon-α-containing liposomes. Int. J. Pharm., 123, 33–39 (1995).
Greig, N. H., Soncrant, T. T., Wozniak, K. M., and Rapoport, S. I., Plasma and tissue pharmacokinetics of human interferon-α in the rat after its intravenous administration. J. Pharmacol. Exp. Ther., 245, 574–580 (1988).
Johns, T. G., Kerry, J. A., Veitch, B. A. J., Mackay, I. R., Tutton, P. J., Tymms, M. J., Cheetham, B. F., Hertzog, P. J., and Linnane, A. W., Pharmacokinetics, tissue distribution, and cell localization of [35S]methionine-labeled recombinant human and murine α-interferons in mice. Cancer Res., 50, 4718–4723 (1990).
Kawahara, K. A., Sekiguchi, A., Kiyoki, E., Ueda, T., Shimamura, K., Kurosaki, Y., Miyaoka, S., Okabe, H., Miyajima, M., and Kimura, J., Effect of TRX-liposomes size on their prolonged circulation in rats. Chem. Pharm. Bull., 51, 336–338 (2003).
Liu, D., Mori, A., and Huang, L., Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. Biochim. Biophys. Acta, 1104, 95–101 (1992).
Nagayasu, A., Uchiyama, K., and Kiwada, H., The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Adv. Drug Deliv. Rev., 40, 75–87 (1999).
Oussoren, C., Zuidema, J., Crommelin, D. J. A., and Storm, G., Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid composition and lipid dose. Biochim. Biophys. Acta, 1328, 261–272 (1997).
Oussoren, C., Storm, G., Crommelin, D. J. A., and Senior, J. H., Liposomes for local sustained drug release. In Senior, J. H. and Radomsky, M. (Eds.). Sustained-Release Injectable Products. Interpharm Press, Denver, pp. 145–157, (2000).
Palleroni, A. V. and Bohoslawec, O., Use of 125I-interferons in pharmacokinetic and tissue distribution studies. J. Interferon Res., 4, 493–498 (1984).
Qiu, J., Wei, X. H., Geng, F., Liu, R., Zhang, J. W., and Xu, Y. H., Multivesicular liposome formulations for the sustained delivery of interferon α-2b. Acta Pharmacol. Sin., 26, 1395–1401 (2005).
Radwanski, E., Perentesis, G., Jacobs, S., Oden, E., Affrime, M., Symchowicz, S., and Zampaglione, N., Pharmacokinetics of interferon α-2b in healthy volunteers. J. Clin. Pharmacol., 27, 432–435 (1987).
Scherphof, G. L., Velinova, M., Kamps, J., Donga, J., van der Want, H., Kuipers, F., Havekes, L., and Daemen, T., Modulation of pharmacokinetic behaviour of liposomes. Adv. Drug Deliv. Rev., 24, 179–191 (1997).
Tümer, A., Kirby, C., Senior, J., and Gregoriadis, G., Fate of cholesterol-rich liposomes after subcutaneous injection into rats. Biochim. Biophys. Acta, 760, 119–125 (1983).
Van Slooten, M. L., Boerman, O., Romøren, K., Kedar, E., Crommelin, D. J. A., and Storm, G., Liposomes as sustained release system for human interferon-γ: biopharmaceutical aspects. Biochim. Biophys. Acta, 1530, 134–145 (2001).
Wai, C. T. and Lok, A. S., Treatment of hepatitis B. J. Gastroenterol., 37, 771–778 (2002).
Wills, R. J., Dennis, S., Spiegel, H. E., Gibson, D. M., and Nadler, P. I., Interferon kinetics and adverse reactions after intravenous, intramuscular and subcutaneous injection. Clin. Pharmacol. Ther., 35, 722–727 (1984).
Yang, L., Yang, W. Z., Bi, D. Z., and Zeng, Q., A novel method to prepare highly encapsulated interferon α-2b containing liposomes for intramuscular sustained release. Eur. J. Pharm. Biopharm., 64, 9–15 (2006).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Li, H., Yang, L., Cheng, G. et al. Encapsulation, pharmacokinetics and tissue distribution of interferon α-2b liposomes after intramuscular injection to rats. Arch. Pharm. Res. 34, 941–948 (2011). https://doi.org/10.1007/s12272-011-0611-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-011-0611-4